1. Home
  2. VYX vs KURA Comparison

VYX vs KURA Comparison

Compare VYX & KURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NCR Voyix Corporation

VYX

NCR Voyix Corporation

HOLD

Current Price

$6.56

Market Cap

980.9M

Sector

N/A

ML Signal

HOLD

Logo Kura Oncology Inc.

KURA

Kura Oncology Inc.

HOLD

Current Price

$11.15

Market Cap

841.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VYX
KURA
Founded
1881
2014
Country
United States
United States
Employees
13500
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
980.9M
841.6M
IPO Year
N/A
2015

Fundamental Metrics

Financial Performance
Metric
VYX
KURA
Price
$6.56
$11.15
Analyst Decision
Strong Buy
Buy
Analyst Count
6
11
Target Price
$13.67
$25.56
AVG Volume (30 Days)
2.2M
1.5M
Earning Date
05-07-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$67,482,000.00
Revenue This Year
N/A
$28.28
Revenue Next Year
N/A
$106.37
P/E Ratio
N/A
N/A
Revenue Growth
N/A
25.24
52 Week Low
$6.02
$5.45
52 Week High
$14.67
$12.49

Technical Indicators

Market Signals
Indicator
VYX
KURA
Relative Strength Index (RSI) 41.88 70.82
Support Level $6.21 $8.80
Resistance Level $7.26 $11.17
Average True Range (ATR) 0.42 0.59
MACD -0.12 0.16
Stochastic Oscillator 12.78 86.05

Price Performance

Historical Comparison
VYX
KURA

About VYX NCR Voyix Corporation

NCR Voyix Corp is a company providing services of digital commerce solutions for retail, restaurant, and digital banking. The company operates in two reportable segments: Retail, and Restaurants. The Retail segment provides software solutions for retailers of all sizes, enhancing operational efficiency and customer experience. The Restaurants segment offers end-to-end technology solutions for food service establishments, improving operational efficiency, and customer satisfaction, and reducing costs. The company derives maximum revenue from Retail segment. Geographically, the company operates in United States, Americas (excluding United States), Europe, Middle East and Africa, and Asia Pacific. It derives maximum revenue from United States.

About KURA Kura Oncology Inc.

Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company develops small-molecule medicines designed to target cancer signaling pathways in oncology and hematology. Its pipeline includes menin inhibitor ziftomenib for the treatment of acute myeloid leukemia and other hematologic malignancies, as well as additional product candidates such as KO-7246 and darolifarnib being evaluated for solid tumors and other diseases.

Share on Social Networks: